Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

The ROCKET AF trial compared rivaroxaban with dose-adjusted warfarin in patients with nonvalvular AF and a prior history of stroke or at least two other additional risk factors for stroke.

Eligible patients were randomly assigned in a 1:1:1 ratio to receive subcutaneous injection of abelacimab at a dose of 150 mg or 90 mg once monthly or oral rivaroxaban at a dose of 20 mg once ...

Novel anticoagulants include dabigatran, rivaroxaban and apixaban. Based on the RE-LY study, a 150-mg dose of dabigatran as compared with warfarin was shown to reduce the rate of stroke ...

Compared with those on the direct oral anticoagulant (DOAC) rivaroxaban, patients taking the 150-mg dose of abelacimab (Anthos Therapeutics) saw a 67% reduction in major or clinically relevant ...

Xarelto is a brand name of the drug rivaroxaban. Medicare covers the cost ... How much a person pays for Xarelto depends on the prescribed dosage, and the coverage provided by their Medicare ...

The prescribed dosage for fluoxetine may depend on a person’s individual treatment plan. Other factors, including your specific diagnosis, body weight, and medical history, may affect your ...